Recent clinical studies indicate that blockade of the renin-angiotensin system is important to prevent stroke, and accumulating results of basic research also indicate the possible involvement of the central renin-angiotensin system in ischaemic brain damage and cognition. When the angiotensin II type 1 receptor is blocked by an angiotensin type 1 receptor blocker, unbound angiotensin II acts preferentially on the angiotensin II type 2 (AT 2 ) receptor. These results suggest the pathophysiological importance of the AT 2 receptor in the clinical use of angiotensin type 1 receptor blockers, which are widely used in patients with hypertension with the expectation of a decrease in the onset of cardiovascular and cerebrovascular disease. We review here the possible roles of AT 2 receptor activation in the brain, focusing on ischaemic stroke, cognitive function and neurogenesis, and potential effects of specific AT 2 receptor agonists.
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The roles of angiotensin receptors in the onset of stroke Angiotensin II (Ang II), which is a potent vasoactive substance in the renin-angiotensin system (RAS), has a variety of physiological actions including vasoconstriction, aldosterone release and cell growth. 1 Previous papers on the brain RAS mainly studied the regulatory mechanism of blood pressure. [2] [3] [4] [5] Recent clinical studies, such as PROGRESS, SCOPE, LIFE and the Jikei Heart Study, indicate that blockade of the RAS is important to prevent stroke. [6] [7] [8] [9] Accumulating results of basic research also indicate the possible involvement of the central RAS in ischaemic brain damage.
The major cardiovascular actions of Ang II have been reported to be mediated by the Ang II type 1 (AT 1 ) receptor, whereas the role of a second receptor subtype known as the Ang II type 2 (AT 2 ) receptor in brain ischaemic lesions is still unknown. It has been reported that AT 2 receptor stimulation antagonises the effects of AT 1 receptor stimulation in most tissues. 1 In the brain, AT 2 receptors are expressed not only in the vascular wall, but also in the thalamus, hypothalamus and specific brain stem nuclei. 10 Previous reports suggest that AT 2 receptor stimulation is involved in axonal regeneration, 11 memory and behaviour. 12, 13 However, the function of AT 2 receptor stimulation in the brain is not yet fully understood.
AT 2 receptor stimulation in ischaemic stroke
Maeda et al. reported that the core lesion area after middle cerebral artery (MCA) occlusion, as well as mean arterial blood pressure, was significantly reduced in angiotensinogen-knockout mice. 14 Walther et al. also reported that a smaller lesion area was observed after MCA occlusion in AT 1 receptor-deficient mice. 15 These results suggest that AT 1 receptor stimulation is involved in the development of brain ischaemic lesions and that blockade of the AT 1 receptor decreases ischaemia at least partly due to lowering of blood pressure.
We examined the possible roles of AT 2 receptor stimulation in ischaemic brain damage using AT 2 receptor-deficient mice. Focal brain ischaemia was induced by MCA occlusion with the intraluminal filament technique. Briefly, after making a midline neck incision, the left common and external carotid arteries were isolated and ligated. A nylon monofilament coated with silicon resin was introduced through a small incision into the common carotid artery and advanced to a position 9 mm distal to the carotid bifurcation, to occlude the MCA. Brain samples were obtained 24 hours after MCA occlusion, and their coronal sections with 1-mm thickness were immediately stained with 2% 2,3,5-triphenyltetrazolium chloride. In wild-type mice (C57BL/6J), the maximal ischaemic area was about 25% of the total area, which is in the territory of the MCA, whereas the ischaemic area of the brain was significantly larger in AT 2 receptor-null mice. 16 The neurological deficit at 24 hours after MCA occlusion was greater in AT 2 receptor-null mice than in wildtype mice. Systolic blood pressure 24 hours after MCA occlusion was not significantly different between these two strains. Cerebral surface blood flow was measured in the core region and peripheral region of the MCA territory by laser-Doppler flowmetry using a flexible fibre-optic extension to the master probe. Cerebral blood flow decreased just after MCA occlusion to about 10% of the basal level in the core region, and to about 60% in the periphery in wild-type mice 24 hours after MCA occlusion, whereas cerebral blood flow in the peripheral region was significantly attenuated in AT 2 receptor-null mice, without a significant change in blood flow in the core region. Superoxide anion production was increased on the occluded side, but not on the non-occluded side. Superoxide production in the ischaemic area was enhanced more markedly in AT 2 receptor-null mice, with an increase in NADPH oxidase activity. These results suggest that AT 2 receptor stimulation has a protective effect on ischaemic brain lesions, at least partly through modulation of cerebral blood flow and superoxide production (figure 1). Moreover, we have reported that treatment with an AT 1 receptor blocker (ARB), valsartan, decreased the ischaemic area and oxidative stress with an increase in cerebral blood flow, but this effect was weaker in AT 2 receptor-null mice, suggesting that AT 2 receptor stimulation is important in the protective effects of ARBs against ischaemic brain damage. 16 The role of AT 2 receptor stimulation in cognitive function Stroke is one of the most important causes of cognitive impairment and dementia in the aging population. Poor cognitive performance significantly impairs social interaction and the quality of life of patients. AT 2 receptors are also reported to be expressed in areas related to learning and control of motor activity, 17, 18 and are upregulated after stroke. 10 Recent studies by Unger and colleagues have demonstrated the possibility that stimulation of AT 2 receptors may promote cell differentiation and regeneration in neuronal tissue, 19 and that AT 2 receptor stimulation supported neuronal survival and neurite outgrowth in response to ischaemia-induced neuronal injury. 20 Moreover, Gallo-Payet et al. demonstrated that Ang II induced neural differentiation and neurite outgrowth via mitogen-activated protein kinase 21 or nitric oxide 22 through AT 2 receptor activation and was involved in cerebellar development. 23 Therefore, after focal brain injury, AT 2 receptor stimulation can prevent damage of neurons or activate neural repair systems. We have examined the possibility that AT 2 receptor stimulation prevents cognitive decline after stroke. We demonstrated that AT 2 receptor mRNA expression was significantly increased in the ischaemic side of the brain after MCA occlusion, and that the passive avoidance rate to evaluate cognitive function was significantly impaired in AT 2 receptor-null mice compared with wild-type mice. Treatment with an ARB, valsartan, prevented the cognitive decline in wild-type mice, Paper SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore but this effect was weaker in AT 2 receptor-null mice, suggesting that AT 2 receptor stimulation during ARB treatment is important. 24 We examined possible signalling mechanisms by which AT 2 receptor stimulation could exert neuroprotective effects and enhance neural differentiation. We focused on methyl methanesulphonate sensitive 2 (MMS2), which belongs to a family of ubiquitin-conjugating enzyme variants that are highly similar to ubiquitin-conjugating enzymes E2 (Ubc), and forms a complex with Ubc-13. 25, 26 The MMS2/Ubc-13 complex has been reported to play an important role in DNA repair through a ubiquitin-proteasome system. 27 DNA damage occurs with central nervous system injury, and defects in repair mechanisms are associated with neurodegenerative diseases. 28 Recently, MMS2 was reported to be highly expressed in the rat brain in late embryonic development and then falls markedly during maturation of the central nervous system, 29 suggesting that MMS2 plays a pivotal role in neuronal development and differentiation. However, the association of MMS2 with central nervous system injury is not well defined. We demonstrated that neurons treated with small interfering (si) RNA of MMS2 failed to exhibit neurite outgrowth and synapse formation. 30 Furthermore, we observed that in ischaemic brain regions, MMS2 was increased in wild-type mice but not in AT 2 receptor-null mice, and that intracerebroventricular administration of MMS2-siRNA resulted in greater impairment of the avoidance rate after MCA occlusion compared with that in control-siRNA-transfected mice. 24 Moreover, we observed that AT 2 receptor-null mice showed impaired social interaction, that is, stress-induced anxiety (unpublished results). The roles of the AT 2 receptor in terms of abnormal behaviour need to be addressed in the future.
Signalling mechanism of AT 2 receptor stimulation in neural protection and differentiation AT 2 receptor stimulation induces neurite outgrowth and regulates neurofilaments in neural cell lines, NG108-15 cells and PC12W cells. 31, 32 Furthermore, a genetic approach indicated that mutations of the AT 2 receptor located on the X-chromosome are found in male and female patients with mental retardation, 13 suggesting that the AT 2 receptor gene is involved in brain development and neural maturation in humans. AT 2 receptor-deficient mice display central neurological anomalies, 33, 34 supporting the notion of important roles of the AT 2 receptor in learning ability and cognition. However, the detailed mechanism of the effect of AT 2 receptor stimulation on neural differentiation and protection is unclear.
We have examined the molecular and signalling mechanism by which AT 2 receptor stimulation induces neural differentiation and protection. 30 We examined the effect of Ang II on MMS2 expression using rat neuronal cells, which express both AT 1 and AT 2 receptors. Administration of Ang II increased MMS2 mRNA expression, which was further enhanced by the addition of an ARB, and we also observed that treatment with an AT 2 receptor agonist, CGP42112A, significantly induced MMS2 mRNA expression, indicating that AT 2 receptor stimulation enhances MMS2 expression in neurons. Moreover, treatment with MMS2-siRNA markedly inhibited the AT 2 receptor-induced increase in the expression of mature neural cell markers compared to treatment with control-siRNA. To further examine the AT 2 receptormediated signalling cascade in MMS2 upregulation, we focused on AT 2 receptor-interacting protein (ATIP) 35 which binds the C-terminal of the AT 2 receptor and Src homology 2 domain-containing protein-tyrosine phosphatase 1 (SHP-1). ATIP (also known as AT 2 receptor-binding protein, ATBP 36 ) is also reported to potentially act as a membrane-associated Golgi protein that dictates delivery of the AT 2 receptor to the cell surface. ATIP was found to be identical to a ubiquitously expressed tumour suppressor protein localised in mitochondria. 37 Therefore, ATIP seems to act as a potential novel early component of the growth and/or differentiation-regulating signalling cascade mediated by the AT 2 receptor. On the other hand, SHP-1 is one of the tyrosine phosphatases activated by AT 2 receptor stimulation and is differentially phosphorylated and activated by neural growth factor in PC12 cells, resulting in it playing a role in neural growth factor-induced neural differentiation. 38 We observed that AT 2 receptor stimulation formed a complex of ATIP and SHP-1, and translocated this complex into the nucleus followed by transactivation of MMS2 (figure 2). 30 Furthermore, increased MMS2 expression mediates inhibitor of DNA binding 1 (Id1) proteolysis and promotes DNA repair. The Id proteins contribute to the regulation of mammalian nervous system development. 39 We observed that Id1 protein level was decreased by AT 2 receptor stimulation, and this decrease was restored by MMS2-siRNA treatment, indicating that MMS2 can promote proteolysis of Id1 by the ubiquitin proteasome system. 30 Moreover, a recent paper described that Ubc-13 works on two different pathways via binding with two different Ubc variants, MMS2 for DNA repair and Uev1A for NF-kB activation. 40 Therefore, we analysed the effects of MMS2 on the DNA repair pathway after AT 2 receptor stimulation and performed quantification of abasic sites in genomic DNA in neurospheres after UV radiation. AT 2 receptor stimulation reduced damaged DNA. Treatment with MMS2-siRNA attenuated this DNA-repairing effect, indicating that AT 2 receptor-induced MMS2 upregulation can increase DNA repair via MMS2.
The possible roles of AT 2 receptor stimulation in cell therapy for stroke Recently, cellular therapy has been focused on as a new therapeutic approach to restore injured neurons in the chronic stage of stroke 41 and to protect neurons from ischaemic-reperfusion damage in the acute phase of stroke, 42 using bone marrow stromal cells (MSC), neural stem cells, 43 haematopoietic stem cells 44 and umbilical cord blood. 45 MSC are characterised by the ability to self-renew in a number of non-haematopoietic tissues, and by their multipotentiality for differentiation into various tissues such as fibroblasts, bone, muscle and cartilage. 46, 47 In addition, MSC can differentiate into cells with some characteristics of neurons and astrocytes after being implanted into the central nervous system in vivo. [48] [49] [50] [51] MSC can also protect neurons by secretion of growth factors and cytokines into the brain. [51] [52] [53] Subsequently, many previous reports have demonstrated that MSC transplantation improves functional recovery after stroke. 50, 51, 54, 55 However, the detailed mechanism of the neuroprotective function of MSC after stroke is completely unknown.
Therefore, we examined the possibility that dele-we examined the possibility that deletion of the AT 2 receptor in MSC could attenuate the cerebroprotective effects of MSC prepared from AT 2 receptor-deficient mice. 56 Wild-type mice were subjected to three hours of focal brain ischaemia, followed by reperfusion (I/R injury). Simultaneously, MSC prepared from wild-type mice, AT 2 receptor-deficient MSC, or saline was injected via the tail vein. Saline-injected mice exhibited around a 50% survival rate after I/R injury six days after MCA occlusion, whereas wild-type MSC injection increased the survival rate up to 80% in mice after I/R injury. Interestingly, AT 2 receptor-deficient MSC-injected mice showed a marked decrease in survival rate after I/R injury, with an increase in the ischaemic area and neurological deficit, brain oedema and inflammatory response such as TNF-a. ARB-treated wild-type MSC-transplanted mice exhibited no operative death until six days after I/R injury, and treatment of AT 2 receptor-null MSC-injected mice with an ARB increased the survival rate up to 80%, similar to that in the wild-type MSC-transplanted group without ARB treatment. These results suggest that Following injection of MSC obtained from green fluorescent protein mice via the tail vein after reperfusion, only a few fluorescent cells were observed in the brain, indicating that only a very small amount of MSC can stay in the ischaemic region. Therefore, it is difficult to consider that injected MSC in situ can act as cellular repair factors. Accordingly, in the present study, we consider that MSC can act as an indirect neuroprotective factor to regulate the production and secretion of growth factors and/or cytokines, rather than as a direct factor through cellular replacement. Taking these findings together, we can postulate that stimulation of AT 2 receptor signalling in MSC plays a pivotal role in the contribution of MSC treatment to brain protection after focal brain ischaemia-reperfusion injury. 
